Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.59 million versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.